Leerink Partnrs Estimates Biogen's Q1 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB - Free Report) - Analysts at Leerink Partnrs cut their Q1 2025 earnings estimates for Biogen in a research report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will post earnings of $2.70 per share for the quarter, down from their prior estimate of $3.84. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Leerink Partnrs also issued estimates for Biogen's FY2027 earnings at $16.45 EPS and FY2028 earnings at $17.95 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

A number of other brokerages also recently weighed in on BIIB. Piper Sandler reaffirmed a "neutral" rating and set a $135.00 price objective (down previously from $138.00) on shares of Biogen in a research report on Tuesday, February 18th. William Blair reiterated an "outperform" rating on shares of Biogen in a research report on Monday, January 13th. The Goldman Sachs Group reduced their price objective on Biogen from $281.00 to $245.00 and set a "buy" rating for the company in a research report on Thursday, February 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of Biogen in a research report on Wednesday, April 16th. Finally, Sanford C. Bernstein began coverage on Biogen in a research note on Tuesday, February 11th. They issued a "market perform" rating and a $160.00 target price on the stock. Eighteen equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $213.15.

Biogen Stock Performance

BIIB stock traded down $2.02 during trading on Wednesday, hitting $116.59. 405,896 shares of the company's stock traded hands, compared to its average volume of 1,350,290. The stock has a fifty day moving average price of $134.29 and a two-hundred day moving average price of $151.20. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. Biogen has a 52 week low of $110.04 and a 52 week high of $238.00. The stock has a market capitalization of $17.07 billion, a price-to-earnings ratio of 10.42, a price-to-earnings-growth ratio of 1.51 and a beta of 0.06.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Larson Financial Group LLC increased its stake in shares of Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock worth $25,000 after acquiring an additional 141 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in Biogen in the 4th quarter worth about $25,000. Opal Wealth Advisors LLC purchased a new stake in shares of Biogen during the 1st quarter worth about $26,000. Colonial Trust Co SC lifted its holdings in shares of Biogen by 9,300.0% during the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock valued at $29,000 after buying an additional 186 shares during the last quarter. Finally, OFI Invest Asset Management bought a new stake in shares of Biogen in the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 87.93% of the company's stock.

Insiders Place Their Bets

In other news, Director Stephen A. Sherwin sold 8,760 shares of the company's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the transaction, the director now owns 11,318 shares in the company, valued at $1,697,926.36. This represents a 43.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.